Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Brunswick Corporation (BC) vs Bristol-Myers Squibb Co (BMY) Price & Performance

Brunswick CorporationTrade
Bristol-Myers Squibb CoTrade

Price performance (Past 24H)

Key statistics

Brunswick Corporation vs Bristol-Myers Squibb Co — how do they compare? Brunswick Corporation trades at $81.32 (market cap $5.28B), while Bristol-Myers Squibb Co trades at $63.61 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 24.6× Brunswick Corporation's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.

BCBMY
Market Cap
$5.28B$129.94B
Sector
Consumer CyclicalHealth
52-Week High
$89.22$65.89
52-Week Low
$58.75$42.60
Enterprise Value
$7.28B$163.92B
Dividend Yield
2.16%3.96%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Brunswick Corporation

Brunswick Corporation (BC) trades at $80.27, down 0.2% on the day, with strong analyst support showing 71% buy ratings and an $85.33 consensus price target. Recent Q2 2026 earnings beat expectations with $1.56 EPS versus $1.19 expected, though the company remains unprofitable with negative net margins. Technical indicators show a bullish trend with current price near pivot point support at $81, while fundamentals reveal mixed performance with solid revenue but profitability challenges.

The outlook remains cautiously optimistic given strong institutional interest and recent earnings beats, but investors face risks from persistent negative profitability and high P/E valuation. Upside potential exists if the company can translate revenue stability into sustained earnings growth, though margin pressures and competitive threats warrant careful monitoring.

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.

BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Brunswick Corporation

Brunswick Corp is the leader in several recreational sectors. The firm is the leading boat manufacturer, and its brands include Mercury and Mariner outboard engines

Read more on BC

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY